Pharmac Committee Gives Wegovy High Funding Priority for New Zealanders With Heart Disease and a BMI of 27 or More
Pharmac's cardiovascular advisory committee provisionally recommended funding Wegovy (semaglutide) at high priority for people with cardiovascular disease and a BMI of 27 or more, RNZ reported. It is not a funding decision: Wegovy remains unfunded in New Zealand, where patients pay the full price, and Pharmac had already placed it on its list of medicines suitable for future funding for weight loss in May. Novo Nordisk welcomed the recommendation.